Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

Linden, Michael; Hadler, D.; G. Hofmann, Stefan

doi:10.1002/(sici)1099-1077(199709/10)12:5<445::aid-hup887>3.0.co;2-2

Public

Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

Published in Human Psychopharmacology Clinical and Experimental • Sep 1, 1997

Authors:

Michael Linden

D. Hadler

Stefan G. Hofmann

Abstract

Generalized anxiety disorders are frequent, chronic, and disabling illnesses for which so far ideal drug treatment is not available. A new promising anxiolytic drug is DN-2327, a non-benzodiazepine isoindoline derivative, which has shown in animals to have anxiolytic, taming, antiaggressive, and ant...

Subject

Anxiolytic

Tolerability

Generalized anxiety disorder

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!